Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Current Deferred Revenue (2016 - 2018)

Historic Current Deferred Revenue for Catalyst Pharmaceuticals (CPRX) over the last 8 years, with Q4 2018 value amounting to $33408.0.

  • Catalyst Pharmaceuticals' Current Deferred Revenue rose 3913.62% to $33408.0 in Q4 2018 from the same period last year, while for Dec 2018 it was $33408.0, marking a year-over-year increase of 3913.62%. This contributed to the annual value of $33408.0 for FY2018, which is 3913.62% up from last year.
  • According to the latest figures from Q4 2018, Catalyst Pharmaceuticals' Current Deferred Revenue is $33408.0, which was up 3913.62% from $21914.0 recorded in Q3 2018.
  • Catalyst Pharmaceuticals' 5-year Current Deferred Revenue high stood at $33408.0 for Q4 2018, and its period low was $3254.0 during Q1 2014.
  • Over the past 5 years, Catalyst Pharmaceuticals' median Current Deferred Revenue value was $18094.0 (recorded in 2016), while the average stood at $16181.7.
  • As far as peak fluctuations go, Catalyst Pharmaceuticals' Current Deferred Revenue skyrocketed by 33513.71% in 2015, and later crashed by 227.43% in 2018.
  • Catalyst Pharmaceuticals' Current Deferred Revenue (Quarter) stood at $4158.0 in 2014, then skyrocketed by 335.14% to $18093.0 in 2015, then increased by 0.01% to $18094.0 in 2016, then skyrocketed by 32.7% to $24011.0 in 2017, then skyrocketed by 39.14% to $33408.0 in 2018.
  • Its Current Deferred Revenue was $33408.0 in Q4 2018, compared to $21914.0 in Q3 2018 and $27184.0 in Q2 2018.